Talk:MDMAI
Latest comment: 8 years ago by Jenks24 in topic Requested move 6 November 2015
| This is the talk page for discussing improvements to the MDMAI article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about MDMAI.
|
Move? (2010)
edit- The following discussion is an archived discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. No further edits should be made to this section.
The result of the move request was: no consensus so not moved. Cybercobra (talk) 06:56, 29 April 2010 (UTC)
{{movereq}}
5,6-Methylenedioxy-N-methyl-2-aminoindane → MDMAI —
- Name is too long and to go along with MDMA, MDAI, MDAT, MMAI, etc}} user:El3ctr0nika 14:36, 19 April 2010 (UTC)
- Strong oppose for now. As it stands the proposal is advocacy of the worst sort: People should use a shorter name; People should use consistent naming. WP:NC is all about what people do use, rather than telling them what they should use. The term MDMA is a common name, and ecstacy was rejected as the article name in this case because of ambiguity. Google shows me more than two million hits for MDMA (your results may differ depending on your location), while MDMAI is far rarer, less than ten thousand, many of them unrelated to this usage of the term. Other articles cited above (MDAI, MDAT, MMAI, etc) may need to be moved (or perhaps moved back?) to more common names, depending on the facts of each case. Andrewa (talk) 20:18, 20 April 2010 (UTC)
- The above discussion is preserved as an archive of a requested move. Please do not modify it. Subsequent comments should be made in a new section on this talk page. No further edits should be made to this section.
Move - 2014 Edition
edit- The following discussion is closed. Please do not modify it. Subsequent comments should be made in a new section.
@Seppi333: @Boghog: This article's name is an absolute abomination, and it sticks out like a sore thumb in comparison to its isomers' titles. Most people on the internet, according to my cursory investigation, call it MDMAI. And there sure as hell isn't anyone in the real world that calls it "5,6-Methylenedioxy-N-methyl-2-aminoindane". I don't have access to the Nichols article, but if he didn't term it MDMAI I'm sure that's just because that name is essentially a "ban me" (or "I'm an analogue") tag in the DEA's eyes. Who's up for a move? Exercisephys (talk) 01:48, 11 February 2014 (UTC)
- Dont think I have enough experience with these types of articles to make an informed decision on the naming convention. Just based upon other articles in its categories, it's a bit longer than usual for those in Category:Entactogens and empathogens, and roughly the same length as the average in Category:Benzodioxoles. Seppi333 (Insert 2¢ | Maintained) 04:21, 11 February 2014 (UTC)
- Support – PMID 21748859 is a secondary source that uses the abbreviation MDMAI. CID 125559 from PubChem also lists it as a synonym. For consistency with the article names of related MDMA, MDAI, MDAT, MMAI, etc substances, I support the move. Boghog (talk) 04:26, 11 February 2014 (UTC)
- @Andrewa: Opinion? Exercisephys (talk) 02:55, 12 February 2014 (UTC)
- Looking at it, thanks! Andrewa (talk) 16:47, 12 February 2014 (UTC)
- The above discussion is closed. Please do not modify it. Subsequent comments should be made in a new section.
Requested move 6 November 2015
edit- The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review. No further edits should be made to this section.
The result of the move request was: moved. Unopposed for over two weeks. Jenks24 (talk) 12:57, 23 November 2015 (UTC)
5,6-Methylenedioxy-N-methyl-2-aminoindane → MDMAI – IUPACs as titles should be used as a last resort. Aethyta (talk) 05:15, 6 November 2015 (UTC) Relisted. Jenks24 (talk) 01:48, 15 November 2015 (UTC)
- Relisting comment. This appears to have been contentious in the past so giving it another week. Jenks24 (talk) 01:48, 15 November 2015 (UTC)
- The above discussion is preserved as an archive of a requested move. Please do not modify it. Subsequent comments should be made in a new section on this talk page or in a move review. No further edits should be made to this section.